Neurogene Inc. (NGNE) Stock Analysis & Investment Frameworks
Neurogene Inc. (NGNE) stock analysis on Invetso. Review Neurogene Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Neurogene Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Neurogene Inc. Key Financial Metrics
- Market Cap: $421.45M
- Revenue: $N/A
- ROE: -45.11%
- ROIC: -53.72%
- Dividend Yield: N/A
About Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.